Navigation Links
ViroPharma To Release 2013 First Quarter Financial Results On May 1, 2013
Date:4/25/2013

EXTON, Pa., April 25, 2013 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) first quarter financial results for 2013 are expected to be released on Wednesday, May 1, 2013 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day.  During the conference call, ViroPharma management will discuss the 2013 first quarter financial results, review clinical data and provide development program updates along with other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com.  An audio archive will be available at the same address until May 15, 2013.  To participate in the conference call, please dial (800) 874-4559 (domestic) and (302) 607-2019 (international).  After placing the call, please tell the operator you wish to join the ViroPharma investor conference call. 

About ViroPharma Incorporated 
ViroPharma Incorporated is an international biopharmaceutical company committed to developing and commercializing novel solutions for physician specialists to address unmet medical needs of patients living with diseases that have few if any clinical therapeutic options. ViroPharma is developing a portfolio of therapeutics for rare and Orphan diseases including C1 esterase inhibitor deficiency, cytomegalovirus (CMV), Friedreich's Ataxia, eosinophilic esophagitis (EoE) and adrenal insufficiency. Our goal is to provide rewarding careers to employees, to create new standards of care in the way serious diseases are treated, and to build international partnerships with the patients, advocates, and health care professionals we serve. ViroPharma's commercial products address
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2012 Financial Results
2. ViroPharma To Participate In Two Upcoming Healthcare Investor Conferences
3. ViroPharma Launches Novel Campaign to Illustrate the Emotional Burden of Hereditary Angioedema
4. ViroPharma Incorporated Reports Third Quarter 2012 Financial Results
5. ViroPharma To Host Analyst And Investor Seminar On September 21, 2012
6. ViroPharma to Present at the Stifel Nicolaus 2012 Healthcare Conference
7. ViroPharma Incorporated Reports Second Quarter 2012 Financial Results
8. ViroPharma To Release 2012 Second Quarter Financial Results On August 9, 2012
9. Berger & Montague, P.C. Reminds Viropharma Shareholders That The Deadline To Petition The Court To Act As Lead Plaintiff Is July 23, 2012
10. ViroPharma To Participate In The JMP Securities Healthcare Conference
11. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... CORAL SPRINGS, Florida , August 3, 2015 ... OFF HOLD -- FN Media Group LLC, PIV757417 ... Partnerships Focus on Developing Orphan Drug Products & ... is now OFF HOLD. Distribution time: 3 Aug ... development agreements between biotech companies, military surgical research ...
(Date:8/3/2015)... FRANCISCO, Calif. , Aug. 3, 2015 /PRNewswire/ ... the treatment of cancer, today announced the promotion ... Debanjan Ray , who previously served ... management, has been promoted to senior vice president ... CytomX, Mr. Ray held positions as the vice ...
(Date:8/3/2015)... OSAKA, Japan and FLORHAM PARK, ... today announced that once-daily naldemedine met its primary and ... for the treatment of opioid-induced constipation (OIC) in adult ... oral, peripherally acting mu-opioid receptor antagonist (PAMORA). This is ... its primary and key secondary endpoints. Study ...
Breaking Medicine Technology:/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 2/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 3/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 4/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 5/OFF HOLD OFF HOLD OFF HOLD -- FN Media Group LLC/ 6CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4
(Date:8/3/2015)... , ... August 03, 2015 , ... ... and development solutions for drugs, biologics and consumer health products, today welcomed the ... for review OPKO’s New Drug Application for a new treatment for chronic kidney ...
(Date:8/3/2015)... FL (PRWEB) , ... August 03, 2015 , ... ... to date of its industry-defining contract lifecycle management solution, as well as announced ... designed to increase the speed and ease of contract management tasks as well ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
(Date:8/3/2015)... ... 03, 2015 , ... A July 13 article from The Daily Mail titled ... Natural Painkiller That Can Last 'For Five Weeks'" discusses the use of stem ... study showed that harvesting stem cell-rich bone marrow from the hip, known as bone ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... today that Joe Williams has joined its growing California employee benefits division. ... service model to his clients. Mr. Williams will be joining the newly integrated ...
Breaking Medicine News(10 mins):Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Novatus Unveils Milestone Software Release 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2
... A new study has dismissed any association between consumption of ... association between total calcium intake//, and consequent changes in body ... intake of calcium. ,More than 19,000 men between ... a 12-year period. All of the study participants consumed a ...
... health benefits. Now, teens, who want that dream weight, can ... obesity at bay, according to a new study. Researchers at ... combined yoga with breathing exercises certainly helped knock off the ... boys participated in a study. They were divided into two ...
... appear to have scaled up following the improvement in ... flu outbreak abated.// , ,According to an official ... been some improvement in the movement of these commodities ... in the last four days. Poultry consumption too has ...
... Information (CIHI) said that despite the government investing a ... of waiting time. // Glenda Yeates, president of the ... and high-priority procedures has increased dramatically. ,But ... much. Statistics show that the number of angioplasties and ...
... study claims that calcium intake was not associated with weight ... published in the American Journal of Clinical Nutrition. ... enrolled in the Health Professionals Follow-up Study were taken as ... between total calcium intake from diet and supplements and changes ...
... eastern Sarawak state of Malaysia is causing concern among Malaysian ... all schools in the area to prevent the disease from ... causes the disease, has so far affected more than a ... peninsular Malaysia, the health ministry will take a clear line ...
Cached Medicine News:
... The ESR-100 is an automated 100-position ESR ... 50 samples daily. The instrument accurately and ... in 1.2ml or 2.0ml ESR-Vacuum Tubes. Results ... Westergren Method) and are available in 30 ...
The CA-500 series quickly and accurately measures up to 5 coagulation parameters. It is the analyzer of choice for low to mid volume laboratories, or as a backup to larger coagulation analyzers....
... Qwik-Let® Premier is our top-of-the-line ... the attributes of the Qwik-Let® ... patented Lan-X feature. The Lan-X ... and protection in the removal ...
... The new Finnpipette Focus from Thermo ... with uncompromising performance. Advanced features such ... .01ul fine volume adjustment on microvolumes help ... in single channel pipettes. The new interchangeable ...
Medicine Products: